EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines).

OBJECTIVE To provide the first update of the EAU guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO). METHODS A systematic literature review was conducted based on the results of a MEDLINE search concentrating on the years 1999-2003. In combination with expert opinions recommendations were made on the usefulness of diagnostic tests, therapeutic options and follow-up. RESULTS During initial assessment the following tests are recommended: medical history, physical examination including digital-rectal examination, International Prostate Symptom Score, urinalysis, serum creatinine and prostate specific antigen measurement, uroflowmetry and post-void residual volume. All other tests are optional or not recommended. Aim of treatment is to improve LUTS and quality of life and to prevent severe BPE-related complications. Development of a 5alpha-reductase type I and II inhibitor and the data of the MTOPS trial providing scientific evidence for a combination therapy were the most significant innovations since the first version. Finally a more detailed knowledge on the natural history with identification of several risk factors for progression is the basis for a risk-profile orientated (preventive) therapy. CONCLUSIONS Updated recommendations for assessment, treatment, and follow-up of patients with LUTS due to BPO are presented.

[1]  J. J. de la Rosette,et al.  Transurethral microwave thermotherapy: the gold standard for minimally invasive therapies for patients with benign prostatic hyperplasia? , 2003, Journal of endourology.

[2]  T. Philp,et al.  Transurethral electrovaporization of the prostate (TUVP) is effective, safe and durable , 2003, Prostate Cancer and Prostatic Diseases.

[3]  R. Roberts,et al.  Natural history of prostatism: risk factors for acute urinary retention. , 1997, The Journal of urology.

[4]  D. Griffiths,et al.  Standardization of terminology of lower urinary tract function: Pressure‐flow studies of voiding, urethral resistance, and urethral obstruction , 1997, Neurourology and urodynamics.

[5]  J. Lam,et al.  Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. , 2003, Urology.

[6]  C. Roehrborn,et al.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. , 2003, The New England journal of medicine.

[7]  Benjamin Lee.  Medical Therapy of Benign Prostatic Hyperplasia , 2005 .

[8]  H. Watanabe,et al.  New concept of BPH: PCAR theory , 1998, The Prostate.

[9]  Eter,et al.  THE EFFECT OF FINASTERIDE ON THE RISK OF ACUTE URINARY RETENTION AND THE NEED FOR SURGICAL TREATMENT AMONG MEN WITH BENIGN PROSTATIC HYPERPLASIA , 2000 .

[10]  J. Oesterling,et al.  A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. , 1998, The Journal of urology.

[11]  Marberger,et al.  Is transurethral resection of the prostate still justified? , 1999, BJU international.

[12]  R. Kirby,et al.  The natural history of benign prostatic hyperplasia: what have we learned in the last decade? , 2000, Urology.

[13]  A. Tubaro.  Side-firing neodymium: YAG laser prostatectomy , 1999 .

[14]  P. Boyle,et al.  Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. , 2002, Urology.

[15]  P. Boyle,et al.  Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. , 1999, Urology.

[16]  A. Zlotta,et al.  Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. , 2003, European urology.

[17]  P. Boyle,et al.  Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. , 2003, Urology.

[18]  T. Karrison,et al.  Serum creatinine measurements in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. , 1997, Urology.

[19]  H. Lepor,et al.  The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. , 1996, The New England journal of medicine.

[20]  Mcneill,et al.  Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled , 1999, BJU international.

[21]  E. Rimm,et al.  Incidence rates and risk factors for acute urinary retention: the health professionals followup study. , 1999, The Journal of urology.

[22]  J. J. de la Rosette,et al.  EAU Guidelines on Benign Prostatic Hyperplasia (BPH) , 2001, European Urology.

[23]  M. Marberger,et al.  The early postoperative morbidity of transurethral resection of the prostate and of 4 minimally invasive treatment alternatives. , 1997, The Journal of urology.

[24]  C. Roehrborn,et al.  The Progression of Benign Prostatic Hyperplasia: Examining the Evidence and Determining the Risk , 2001, European Urology.

[25]  P. Boyle,et al.  [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study]. , 2002, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[26]  F. Debruyne,et al.  Sustained-Release Alfuzosin, Finasteride and the Combination of Both in the Treatment of Benign Prostatic Hyperplasia , 1998, European Urology.

[27]  T. Larson,et al.  Clinical results of microwave thermotherapy for benign prostatic hyperplasia. , 2000, Journal of endourology.

[28]  AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. , 2003, The Journal of urology.

[29]  M. Marberger,et al.  Optimising the medical management of benign prostatic hyperplasia. , 2004, European urology.

[30]  C. Chapple.  Alpha adrenoceptor antagonists in the year 2000: is there anything new? , 2001, Current opinion in urology.

[31]  Anthony Costello,et al.  A systematic review of holmium laser prostatectomy for benign prostatic hyperplasia. , 2004, The Journal of urology.

[32]  M. Emberton,et al.  Could self-management challenge pharmacotherapy as a long-term treatment for uncomplicated lower urinary tract symptoms? , 2004, Current opinion in urology.

[33]  T. Peters,et al.  Transurethral incision compared with transurethral resection of the prostate for bladder outlet obstruction: a systematic review and meta-analysis of randomized controlled trials. , 2001, The Journal of urology.

[34]  K. Dreikorn.  The role of phytotherapy in treating lower urinary tract symptoms and benign prostatic hyperplasia , 2002, World Journal of Urology.